SmithKline Beecham (LSE:SB; SBH) returned development and commercialization rights to CLTR's Bexxar cancer therapy outside the U.S. As a result, CLTR will be eligible for less than the $76 million in milestones
Read the full 326 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury